Harrow Health (NASDAQ:HROW) subsidiary Stowe Pharmaceuticals in-licenses worldwide rights to TGV Health’s antimicrobial agent Zian for complex bacterial, fungal and viral infections in the eye and ear. The initial primary indication will be adenoviral conjunctivitis. Secondary indications include mixed bacterial-viral infections, keratitis, endophthalmitis and corneal ulcers.
Financial terms are not disclosed.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.